Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Multiple Cancer Types

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
Hematologic, Myelodysplastic Syndrome
I
Strickland, Stephen
NCT02942290
VICCHEM16134

Pevonedistat and Azacitidine in Treating Patients with Refractory or Relapsed Myelodysplastic Syndrome or Myelodysplastic Syndrome / Myeloproliferative Neoplasm Who Fail Primary Therapy

Myelodysplastic Syndrome

This phase II trial studies how well pevonedistat and azacitidine work in treating patients with myelodysplastic syndrome or myelodysplastic syndrome / myeloproliferative neoplasm that has failed primary therapy, that does not respond to treatment (refractory), or has come back (recurrent). Pevonedistat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Myelodysplastic Syndrome
II
Savona, Michael
NCT03238248
VICCHEM16146

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Multiple Cancer Types

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B) of ASTX030. Phase 2 is a randomized open-label crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the final oral ASTX030 tablet to SC azacitidine. The duration of the study is expected to be approximately 36 months.
Leukemia, Myelodysplastic Syndrome, Phase I
I/II/III
Savona, Michael
NCT04256317
VICCHEMP19146

Nivolumab with or without Azacitidine in Treating Patients with Recurrent Resectable Osteosarcoma

Multiple Cancer Types

This phase I / II trial studies the best dose and side effects of azacitidine and how well it works with or without nivolumab in treating patients with osteosarcoma that has come back (recurrent) and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and azacitidine together may work better compared to nivolumab alone in treating patients with osteosarcoma.
Phase I, Sarcoma
I/II
Borinstein, Scott
NCT03628209
VICCPED2012

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: